This approach is based on the Swedish Breast Cancer Group’s decision to maintain the ≥ 10% cut-off for both ER and PR positivity, due to limited scientific evidence to support the ASCO and College of American Pathologists (CAP) guidelines lowering the threshold to ≥ 1% [18]. The gene discussed is ESR1; the disease is breast carcinoma.